(Q24633820)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22644293%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

title

Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22644293%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

1 reference

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22644293%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Antonella Pietragalla

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22644293%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Rosa De Vincenzo

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22644293%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

Giorgia Mangili

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22644293%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

author name string

G Scambia

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22644293%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

G Amadio

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22644293%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

A di Legge

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22644293%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

V Masciullo

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22644293%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

M Di Stefano

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22644293%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

G Citterio

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22644293%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

M Mantori

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22644293%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

A Lambiase

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22644293%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

C Bordignon

13

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22644293%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

language of work or name

English

0 references

publication date

29 May 2012

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22644293%20AND%20SRC:MED&resulttype=core&format=json

British Journal of Cancer

2 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22644293%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

volume

107

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22644293%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22644293%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

page(s)

37-42

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22644293%20AND%20SRC:MED&resulttype=core&format=json

An endotoxin-induced serum factor that causes necrosis of tumors

2 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3389423

7 April 2017

Global cancer statistics

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3389423

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3389423

Imaging tumor-stroma interactions during chemotherapy reveals contributions of the microenvironment to resistance

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3389423

Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3389423

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3389423

Phase I clinical and magnetic resonance imaging study of the vascular agent NGR-hTNF in patients with advanced cancers (European Organization for Research and Treatment of Cancer Study 16041).

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3389423

Phase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3389423

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3389423

Antiangiogenic drugs in ovarian cancer.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3389423

Impaired angiogenesis in aminopeptidase N-null mice

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3389423

Efficiency of recombinant human TNF in human cancer therapy

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3389423

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3389423

Crucial role for interferon gamma in the synergism between tumor vasculature-targeted tumor necrosis factor alpha (NGR-TNF) and doxorubicin

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3389423

Reduced growth, increased vascular area, and reduced response to cisplatin in CD13-overexpressing human ovarian cancer xenografts

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3389423

Use of CA-125 to Assess Response to New Agents in Ovarian Cancer Trials

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3389423

Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3389423

Enhancement of tumor necrosis factor alpha antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13).

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3389423

Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3389423

Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer.

27 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3389423

Chromogranin A restricts drug penetration and limits the ability of NGR-TNF to enhance chemotherapeutic efficacy.

30 May 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.233

Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.233

Phase II study of asparagine-glycine-arginine-human tumor necrosis factor alpha, a selective vascular targeting agent, in previously treated patients with malignant pleural mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.233

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.233

Assessment of tumor response as a surrogate endpoint of survival in recurrent/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.233

Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-alpha

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.233

Targeting TNF- to Neoangiogenic Vessels Enhances Lymphocyte Infiltration in Tumors and Increases the Therapeutic Potential of Immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.233

Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.233

Defining the optimal biological dose of NGR-hTNF, a selective vascular targeting agent, in advanced solid tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FBJC.2012.233

Immunoregulatory activity of recombinant human tumor necrosis factor (TNF)-alpha: induction of TNF receptors on human T cells and TNF-alpha-mediated enhancement of T cell responses

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22644293

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Promise of new vascular-disrupting agents balanced with cardiac toxicity: is it time for oncologists to get to know their cardiologists?

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/22644293

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/BJC.2012.233

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22644293%20AND%20SRC:MED&resulttype=core&format=json

Dimensions Publication ID

2 February 2020

1047029393

0 references

1 reference

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22644293%20AND%20SRC:MED&resulttype=core&format=json

2 February 2020

PubMed publication ID

22644293

2 references

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:22644293%20AND%20SRC:MED&resulttype=core&format=json